Common Technical Document

Common Technical Document (CTD)

Diagram of the Common Technical Document structure

The Common Technical Document (CTD) is a set of specifications for a dossier for the registration of medicines. It is used by regulatory authorities in several countries to ensure that the data submitted by pharmaceutical companies is comprehensive and standardized. The CTD is a harmonized format that facilitates the submission of information to regulatory agencies, thereby streamlining the approval process for new drugs.

Structure of the CTD

The CTD is divided into five modules:

Module 1: Administrative Information and Prescribing Information

Module 1 is region-specific and contains administrative documents and prescribing information. This module is not harmonized and varies according to the requirements of each regulatory authority.

Module 2: Common Technical Document Summaries

Module 2 provides the overall summary of the quality, nonclinical, and clinical information. It includes the following sections:

• Quality Overall Summary (QOS)
• Nonclinical Overview
• Clinical Overview
• Nonclinical Written and Tabulated Summaries
• Clinical Summary

Module 3: Quality

Module 3 contains the information on the quality of the drug substance and drug product. It includes detailed data on the manufacturing process, control of materials, and stability testing.

Module 4: Nonclinical Study Reports

Module 4 includes the nonclinical study reports, which cover pharmacology, pharmacokinetics, and toxicology studies. These studies are essential for understanding the safety profile of the drug.

Module 5: Clinical Study Reports

Module 5 contains the clinical study reports and related information. It includes data from clinical trials that demonstrate the efficacy and safety of the drug in humans.

Purpose and Benefits

The CTD format was developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) to simplify the submission process for pharmaceutical companies and regulatory authorities. By using a standardized format, the CTD reduces the time and resources needed for the preparation and review of dossiers. It also facilitates simultaneous submissions to multiple regulatory agencies, thereby accelerating the availability of new medicines to patients.

Implementation

The CTD is widely accepted by regulatory authorities in regions such as the European Union, Japan, and the United States. It is also used by other countries that have adopted the ICH guidelines. The CTD has become the standard format for drug registration applications, replacing the previously diverse and region-specific submission requirements.

Related Pages

• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
• Drug development
• Regulatory affairs
• Pharmacovigilance